miR-181b在星形细胞瘤中的表达及其临床意义

Differential expression of miR-181b in astrocytoma and clinical significance

目的分析星形细胞瘤中miR-181b的表达及其与临床意义。方法选取星形细胞瘤标本84例,以20例癌旁组织为对照,采用Real-timePCR对组织中miR-181b的含量进行测定。结果 miR-181b在星形细胞瘤组织中含量显著下调,差异有统计学意义(P=0.0087)。miR-181b的表达与患者预后密切相关,低表达miR-181b的患者预后较差,而高表达miR-181b的患者预后良好(P=0.035)。miR-181b的表达与患者年龄、性别和WHO分级无统计学意义(P>0.05)。结论 miR-181b在星形细胞瘤组织中表达显著降低,且其表达量与患者的存活时间密切相关,提示其可能为抑癌基因参与了星形细胞瘤的发生与发展,具有重要临床诊疗意义。

Objective To determine the miR-181b expression in astrocytomas and analyze the relationship between miR-181b and clinical features. Methods Real-time PCR was used to quantify the miR-18lb expression in 84 astrocytomas and 20 normal adjacent tissues, and the relationship of miR-181b expression and clinical pathology features was analyzed. Results The miR-181b expression in astrocytomas was down-regulated compared to normal adjacent tissues （P = 0. 0087）. Furthermore, Kaplan-Meicr survival analysis showed that low expression of miR-181b was significantly associaled with poor patient survival （P = 0.035 ）. There was no relationship between miR-181b and gender, age and WHO grade. Conclusion miR-181b was down-regulated in astrocytomas and its low expression was closely correlated with poor patient survival which indicates that miR-181b may represent a potential indicator in the diagnosis, therapeutic effect and prognosis of astrocytoma.